NCT06250946
Efficacy and Safety of HRS-7535 Tablets in Obese Subjects .
A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Phase ⅡStudy to Evaluate the Efficacy and Safety of HRS-7535 in Obese Subjects
Shandong Suncadia Medicine Co., Ltd.·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Overweight and Obesity
- Drug/Device/Intervention
- HRS-7535;Placebo
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Shandong Suncadia Medicine Co., Ltd.
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Feb 01, 2024
- End date
- Feb 01, 2025
- Enrollment
- 225 participants
Primary outcome
Percent change in body weight from baseline at Week 26
Summary
The aim of this trial is to evaluate the efficacy and safety of HRS-7535 in Chinese Obese
 Subjects.
ICD-10 classifications
ObesityOther obesityObesity due to excess caloriesObesity, unspecifiedObesity and other hyperalimentation
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06250946
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06250946 through Pure Global AI's free database. This Phase 2 trial is sponsored by Shandong Suncadia Medicine Co., Ltd. and is currently Not yet recruiting. The study focuses on Overweight and Obesity. Target enrollment is 225 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.